Storia in 7 fonti

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus chemotherapy.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo2 g fa

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus chemotherapy.

originale

cnbc.com2 g fa

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Akeso and Summit Therapeutics' bispecific antibody ivonescimab (PD-1/VEGF) reduced mortality risk by 34% in a Phase 3 China trial, extending median overall survival to 27.9 months vs. 23.7 months for standard PD-1 plus chemotherapy in squamous NSCLC. The data reignite the debate over whether PD-1/VEGF combos can succeed Keytruda ($30B+ in annual sales) as the standard-of-care backbone, though generalizability outside China remains unconfirmed until Harmoni-3 global results land in H2 2026.

Leggi questa versione → originale

biopharmadive.com2 g fa

Akeso, Summit drug extends survival in closely watched lung cancer trial

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."

Leggi questa versione → originale

statnews.com2 g fa

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso and Summit Therapeutics' ivonescimab reduced the risk of death by 34% in squamous non-small cell lung cancer patients versus standard treatment, in a Phase III trial published in The Lancet. For biotech and pharma-adjacent tech buyers, the result validates dual-mechanism oncology biologics and strengthens Summit's pipeline valuation ahead of potential ex-China regulatory filings.

Leggi questa versione → originale

thenextweb.com1 g fa

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's plenary in 61 years, targeting a $20B market.

Leggi questa versione → originale

scmp.com1 g fa

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Leggi questa versione → originale

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

Confronto fonti

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Akeso, Summit drug extends survival in closely watched lung cancer trial

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso lung cancer drug trial raises hopes in US$20b market

Timeline cronologica

Akeso, Summit drug extends survival in closely watched lung cancer trial

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

Akeso lung cancer drug trial raises hopes in US$20b market

Akeso lung cancer drug cuts death risk 34% in landmark trial

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

Confronto fonti

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Akeso, Summit drug extends survival in closely watched lung cancer trial

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso lung cancer drug trial raises hopes in US$20b market

Timeline cronologica

Akeso, Summit drug extends survival in closely watched lung cancer trial

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

Akeso lung cancer drug trial raises hopes in US$20b market

Akeso lung cancer drug cuts death risk 34% in landmark trial